drugset / Trial / NCT00863161

Renal Impairment Study

NCT00863161

Phase 1 Completed 23 enrolled AstraZeneca
Non-randomizedSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to see how quickly AZD3355 is taken up in to the blood and leaves the blood in people with normal kidney function or with different degrees of reduced kidney function.

Timeline

Start
2009-03
Primary completion
2010-02
Completion
2010-02

Drugs

EvaluationDrugModalityDoseRoute
Subject lesogaberan Small molecule 130 mg Oral